Lower doses are furthermore superior in enabling CD4+ and CD8+ T-cell tumor infiltration and changing tumor-associated macrophages from an immune inhibitory M2-like polarization toward an immune stimulatory M1-like phenotype. Here, CD8A is linked to neoplasm.